Chemical Compound Review:
Befibrat 2-[4-[2-[(4-chlorophenyl) carbonylamino]eth...
Synonyms:
Bezabeta, Azufibrat, BezaLande, BezaPuren, Bezacur, ...
Shoda,
Inada,
Tsuji,
Kusama,
Ueda,
Ikegami,
Suzuki,
Sugiyama,
Cohen,
Tanaka,
Scatena,
Nocca,
Sole,
Rumi,
Puggioni,
Remiddi,
Bottoni,
Ficarra,
Giardina,
Tanaka,
Kohno,
Yoshitani,
Takashima,
Okumura,
Murakami,
Hosokawa,
Desideri,
Croce,
Tucci,
Passacquale,
Broccoletti,
Valeri,
Santucci,
Ferri,
Niho,
Takahashi,
Kitamura,
Shoji,
Itoh,
Noda,
Sugimura,
Wakabayashi,
- Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. Eisenberg, S., Gavish, D., Oschry, Y., Fainaru, M., Deckelbaum, R.J. J. Clin. Invest. (1984)
- Severe reversible renal failure with bezafibrate. Lipkin, G.W., Tomson, C.R. Lancet (1993)
- Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., Hosokawa, M. Cancer Res. (2001)
- Bezafibrate as differentiating factor of human myeloid leukemia cells. Scatena, R., Nocca, G., Sole, P.D., Rumi, C., Puggioni, P., Remiddi, F., Bottoni, P., Ficarra, S., Giardina, B. Cell Death Differ. (1999)
- Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Niho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., Noda, T., Sugimura, T., Wakabayashi, K. Cancer Res. (2003)
- Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. Haim, M., Benderly, M., Boyko, V., Goldenberg, I., Tanne, D., Battler, A., Goldbourt, U., Behar, S. Coron. Artery Dis. (2006)
- Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. Mann, C.J., Yen, F.T., Grant, A.M., Bihain, B.E. J. Clin. Invest. (1991)
- Hemoglobin Rahere, a human hemoglobin variant with amino acid substitution at the 2,3-diphosphoglycerate binding site. Functional consequences of the alteration and effects of bezafibrate on the oxygen bindings. Sugihara, J., Imamura, T., Nagafuchi, S., Bonaventura, J., Bonaventura, C., Cashon, R. J. Clin. Invest. (1985)
- Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. Kleinman, Y., Eisenberg, S., Oschry, Y., Gavish, D., Stein, O., Stein, Y. J. Clin. Invest. (1985)
- Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Ericsson, C.G., Hamsten, A., Nilsson, J., Grip, L., Svane, B., de Faire, U. Lancet (1996)
- Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Kjørholt, C., Akerfeldt, M.C., Biden, T.J., Laybutt, D.R. Diabetes (2005)
- Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Greten, H., Beil, F.U., Schneider, J., Weisweiler, P., Armstrong, V.W., Keller, C., Klör, H.U., von Hodenberg, E., Weidinger, G., Eskötter, H. Am. J. Med. (1994)
- Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Jones, I.R., Swai, A., Taylor, R., Miller, M., Laker, M.F., Alberti, K.G. Diabetes Care (1990)
- Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. Desideri, G., Croce, G., Tucci, M., Passacquale, G., Broccoletti, S., Valeri, L., Santucci, A., Ferri, C. J. Clin. Endocrinol. Metab. (2003)
- Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Djouadi, F., Aubey, F., Schlemmer, D., Ruiter, J.P., Wanders, R.J., Strauss, A.W., Bastin, J. Hum. Mol. Genet. (2005)
- Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Matsui, H., Okumura, K., Kawakami, K., Hibino, M., Toki, Y., Ito, T. Diabetes (1997)
- Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. Gross, V., Schneider, W., Schunck, W.H., Mervaala, E., Luft, F.C. J. Am. Soc. Nephrol. (1999)
- Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Jonkers, I.J., Smelt, A.H., Ledeboer, M., Hollum, M.E., Biemond, I., Kuipers, F., Stellaard, F., Boverhof, R., Meinders, A.E., Lamers, C.H., Masclee, A.A. Gut (2003)
- Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Kyrklund, C., Backman, J.T., Kivistö, K.T., Neuvonen, M., Laitila, J., Neuvonen, P.J. Clin. Pharmacol. Ther. (2001)
- L-lactate dehydrogenase A4- and A3B isoforms are bona fide peroxisomal enzymes in rat liver. Evidence for involvement in intraperoxisomal NADH reoxidation. Baumgart, E., Fahimi, H.D., Stich, A., Völkl, A. J. Biol. Chem. (1996)
- Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Cabrero A, n.u.l.l., Alegret, M., Sánchez, R.M., Adzet, T., Laguna, J.C., Vázquez, M. Diabetes (2001)
- Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Schulzeck, P., Bojanovski, M., Jochim, A., Canzler, H., Bojanovski, D. Lancet (1988)
- Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Ståhlberg, D., Reihnér, E., Rudling, M., Berglund, L., Einarsson, K., Angelin, B. Hepatology (1995)
- The interaction of lipophilic drugs with intestinal fatty acid-binding protein. Velkov, T., Chuang, S., Wielens, J., Sakellaris, H., Charman, W.N., Porter, C.J., Scanlon, M.J. J. Biol. Chem. (2005)
- Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. Djouadi, F., Aubey, F., Schlemmer, D., Bastin, J. J. Clin. Endocrinol. Metab. (2005)
- Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. Jonkers, I.J., Smelt, A.H., Hattori, H., Scheek, L.M., van Gent, T., de Man, F.H., van der Laarse, A., van Tol, A. J. Lipid Res. (2003)
- Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. Shoda, J., Inada, Y., Tsuji, A., Kusama, H., Ueda, T., Ikegami, T., Suzuki, H., Sugiyama, Y., Cohen, D.E., Tanaka, N. J. Lipid Res. (2004)
- Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Homma, Y., Ozawa, H., Kobayashi, T., Yamaguchi, H., Sakane, H., Mikami, Y., Mikami, Y., Nakamura, H. Atherosclerosis (1994)
- Dynamin-like protein 1 is involved in peroxisomal fission. Koch, A., Thiemann, M., Grabenbauer, M., Yoon, Y., McNiven, M.A., Schrader, M. J. Biol. Chem. (2003)
- Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. Seiler, C., Suter, T.M., Hess, O.M. J. Am. Coll. Cardiol. (1995)
- Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Ruotolo, G., Ericsson, C.G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J., de Faire, U., Hamsten, A. J. Am. Coll. Cardiol. (1998)